Home › Post-COVID Conditions (Long COVID) › Kansas › Overland Park
Post-COVID Conditions (Long COVID) clinical trials in Overland Park, KS
3 studies for Post-COVID Conditions (Long COVID) are looking for participants at sites in and around Overland Park (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
RecruitingPhase 3
- University of Kansas Medical Center, Fairway · 3 mi away
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine
RecruitingPhase 3Healthy volunteers welcome
- Invivyd Investigative Site, Overland Park
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
RecruitingPhase 1Healthy volunteers welcome
- ICON Clinical Research: Lenexa, Lenexa · 4 mi away
About Post-COVID Conditions (Long COVID)
Anyone who had COVID-19 can have ongoing symptoms. Learn about post-COVID conditions (long COVID), including symptoms, diagnosis, treatments, and prevention.
More about Post-COVID Conditions (Long COVID) on MedlinePlus
Post-COVID Conditions (Long COVID) trials in other cities
- New York City, NY15 studies
- Houston, TX13 studies
- Boston, MA13 studies
- Baltimore, MD12 studies
- Chicago, IL11 studies
- Washington, DC10 studies
- San Francisco, CA8 studies
- Durham, NC8 studies
- Atlanta, GA8 studies
- San Diego, CA7 studies
- Los Angeles, CA6 studies
- Pittsburgh, PA6 studies
Other studies in Overland Park
- Non-Small Cell Lung Cancer16 studies
- Acute Myeloid Leukemia11 studies
- Lung Cancer11 studies
- Breast Cancer10 studies
- Atrial Fibrillation8 studies
- Colorectal Cancer8 studies
- Obesity7 studies
- Pancreatic Cancer7 studies
- Prostate Cancer7 studies
- Melanoma6 studies
- Overweight6 studies
- Ovarian Cancer6 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.